axsome

FDA Grants Priority Review to Axsome Therapeutics’ AXS-05 for Alzheimer’s Agitation, Accelerating Potential Approval for a Critical Unmet Need

The U.S. Food and Drug Administration (FDA) has granted priority review to Axsome Therapeutics’ supplemental New Drug Application (sNDA) for…